RecruitingPhase 1NCT07159126

A Study of DS3610a in Participants With Advanced Solid Tumor

A Phase 1, Open-label, Multicenter, First-in-Human Trial of DS3610a in Participants With Advanced Solid Tumor

Sponsor

Daiichi Sankyo

Enrollment

70 participants

Start Date

Oct 9, 2025

Study Type

INTERVENTIONAL

Conditions

Solid Tumors Metastatic Solid Tumors

Summary

This study is designed to assess the safety, tolerability, and efficacy of DS3610a, given as a single agent to participants with advanced or metastatic solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DS3610a for people with metastatic solid tumors and solid tumors. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDS3610a

Participants will receive DS3610a at the target dose. Treatment will continue until radiographic disease progression, as determined by the investigator, or until another reason for discontinuation of trial intervention occurs.